Intended for healthcare professionals

Rapid response to:

Head To Head

Should we rename low risk cancers?

BMJ 2019; 364 doi: (Published 23 January 2019) Cite this as: BMJ 2019;364:k4699

Rapid Response:

Re: Should we rename low risk cancers?

I agree with Dr Sundar.

Why in the name of commonsense, don’t we leave things alone?

A cancer is a cancer. Be it locally malignant or metastasizing. Slow growing or quick growing.

But please explain it to the patient. And explain it to the insurance companies.

Long time passing, maybe sixty years ago? William Boyd (Scots born and bred, Canadian professor) wrote: carry out histology of prostates of over 80s and you will find malignant cells in most of the deceased’s prostates.
Had you had the ability, the desire, the passion to assault all those prostates while the person was alive, you would have made the poor person miserable, perhaps put on tranquilizers. Who would have gained? The insurance companies, perhaps the urologists.

Please, dear doctors! Treat the patient, guide the patient. Stop treating laboratory results, diagnostic labels.

Dr JK Anand
On the brink of 87th birthday
(At the moment, my prostate is behaving. Who knows about tomorrow?)

Competing interests: No competing interests

25 January 2019
JK Anand
Retired doctor
Free spirit